Login / Signup

Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al .

Jeffrey S WeberMario MandalaPaolo Antonio AsciertoJames Larkin
Published in: Journal for immunotherapy of cancer (2022)
Keyphrases
  • phase iii
  • phase ii
  • open label
  • clinical trial
  • early stage
  • double blind
  • placebo controlled
  • randomized controlled trial